Abstract
In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histologically characterized by rich distribution of the microvascular network consisting of the immature capillaries, lymphatics and venules, and this microvascular network could be the target of the new pharmacotherapy in addition to the direct action on the accumulated B lymphocytes. We have established the animal model of the gastric MALT lymphoma by the Helicobacter heilmannii (H. heilmannii) peroral infection of C57BL/6 mice. The disease induced by this model is very similar to the human counterpart, because of the lymphoepithelial lesion characteristic of the human MALT lymphoma as well as the rich vascularization and localization of vascular endothelial growth factor (VEGF) and its receptors, Flt-1, Flk-1 and Flt-4. By administering VEGF receptor antibodies or celecoxib, one of the cyclooxygenase 2 inhibitors, we were able to induce a significant decrease in the size of the tumor and the apoptotic changes of the endothelial cells of the microvascular network. These antiangiogenic strategies were suggested to be candidates for the new pharmacological treatment of gastric MALT lymphoma, when other treatments are not effective.
Keywords: Gastric MALT lymphoma, angiogenesis, lymphangiogenesis, VEGF, Flt-1, Flk-1, Flt-4, celecoxib.
Current Pharmaceutical Design
Title:New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib
Volume: 20 Issue: 7
Author(s): Masahiko Nakamura, Tetsufumi Takahashi, Hidenori Matsui, Shinichi Takahashi, Somay Y. Murayama, Hidekazu Suzuki and Kanji Tsuchimoto
Affiliation:
Keywords: Gastric MALT lymphoma, angiogenesis, lymphangiogenesis, VEGF, Flt-1, Flk-1, Flt-4, celecoxib.
Abstract: In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histologically characterized by rich distribution of the microvascular network consisting of the immature capillaries, lymphatics and venules, and this microvascular network could be the target of the new pharmacotherapy in addition to the direct action on the accumulated B lymphocytes. We have established the animal model of the gastric MALT lymphoma by the Helicobacter heilmannii (H. heilmannii) peroral infection of C57BL/6 mice. The disease induced by this model is very similar to the human counterpart, because of the lymphoepithelial lesion characteristic of the human MALT lymphoma as well as the rich vascularization and localization of vascular endothelial growth factor (VEGF) and its receptors, Flt-1, Flk-1 and Flt-4. By administering VEGF receptor antibodies or celecoxib, one of the cyclooxygenase 2 inhibitors, we were able to induce a significant decrease in the size of the tumor and the apoptotic changes of the endothelial cells of the microvascular network. These antiangiogenic strategies were suggested to be candidates for the new pharmacological treatment of gastric MALT lymphoma, when other treatments are not effective.
Export Options
About this article
Cite this article as:
Nakamura Masahiko, Takahashi Tetsufumi, Matsui Hidenori, Takahashi Shinichi, Murayama Y. Somay, Suzuki Hidekazu and Tsuchimoto Kanji, New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib, Current Pharmaceutical Design 2014; 20 (7) . https://dx.doi.org/10.2174/13816128113199990420
DOI https://dx.doi.org/10.2174/13816128113199990420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine <i>Cedrus deodara</i> (Bark) Essential Oil Induces Apoptosis in Human Colon Cancer Cells by Inhibiting Nuclear Factor kappa B
Current Topics in Medicinal Chemistry The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma
Current Pharmaceutical Design Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery G Proteins in Drug Screening: From Analysis of Receptor-G Protein Specificity to Manipulation of GPCR-Mediated Signalling Pathways
Current Pharmaceutical Design Chromosomal Aberrations and Genomic Instability Induced by Topoisomerase- Targeted Antitumour Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Curcumin: A Boon to Colonic Diseases
Current Drug Targets Antiangiogenic Therapies in Non-Hodgkin's Lymphoma
Current Cancer Drug Targets Tumor Stroma Manipulation By MSC
Current Drug Targets Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers